ImmunoCellular Therapeutics, Ltd.
(Public, OTC:IMUC) Watch this stockFind more results for
IMUC
Advertisement
Events
Sep 11, 2009
IMMUNOCELLULAR THERAPEUTICS at Rodman & Renshaw Annual Global Investment Conference
|
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -124.70% | -74.62% |
| Return on average equity | -140.39% | -77.06% |
| Employees | 2 | - |
Address
Website links
ImmunoCellular Therapeutics, Ltd. discussed on blogs
November 23rd CEOcast Weekly Newsletter : Stock-Profiles.com
- CEOCastNews
- Stock-Profiles.com
- 7 hours ago
ImmunoCellular Therapeutics, Ltd. discussions
View all discussions »Description
ImmunoCellular Therapeutics, Ltd. is a development stage company that is seeking to develop and commercialize therapeutics to fight cancer using the immune system. The Company’s product candidate portfolio includes peptide based cellular immunotherapies targeting cancer stem cells, cellular immunotherapies targeting cancer antigens and monoclonal antibodies to diagnose and treat different cancers. As of December 31, 2008, the products under development include ICT-121, ICT-107, ICT-109, ICT-037, ICT-69 and ICT-Diagnostic-SCLC. In February 2008, the Company acquired certain monoclonal antibody related technology owned by Molecular Discoveries LLC (Molecular Discoveries).
Officers and directors
| John S. Yu M.D. | Chairman of the Board | |
| Manish Singh Ph.D. | President, Chief Executive Officer, Director | |
| C. Kirk Peacock | Chief Financial Officer, Treasurer | |
| Jacqueline Brandwynne | Director | |
| Richard A. Cowell | Director | |
| Robert L. Martuza M.D. | Director | |
| Navdeep Jaikaria | Director |